Ken Suzuki

Ken Suzuki

Auto-generated profile, based on publicly available information

Ken Suzuki

Department of Statistical Genetics, Graduate School of Medicine, The University of Osaka, Suita, Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SSSaori Sakaue
Saori Sakaue
MKMasahiro Kanai
Masahiro Kanai
Yosuke TanigawaYosuke Tanigawa
Yosuke Tanigawa
JKJuha Karjalainen
Juha Karjalainen
MKMitja Kurki
Mitja Kurki
YOYukinori Okada
Yukinori Okada

8 June 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KIKazuyoshi Ishigaki
Kazuyoshi Ishigaki
MAMasato Akiyama
Masato Akiyama
MKMasahiro Kanai
Masahiro Kanai
ATAtsushi Takahashi
Atsushi Takahashi
EKEiryo Kawakami
Eiryo Kawakami
YKYoichiro Kamatani
Yoichiro Kamatani

4 February 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KSKen Suzuki
Ken Suzuki
MAMasato Akiyama
Masato Akiyama
KIKazuyoshi Ishigaki
Kazuyoshi Ishigaki
MKMasahiro Kanai
Masahiro Kanai
JHJun Hosoe
Jun Hosoe
TKTakashi Kadowaki
Takashi Kadowaki

1 May 2007 in Circulation
Verified
Journal Article
Closed access
SFSatsuki Fukushima
Satsuki Fukushima
AVAnabel Varela-Carver
Anabel Varela-Carver
SCSteven R. Coppen
Steven R. Coppen
KYKenichi Yamahara
Kenichi Yamahara
LFLeanne E. Felkin
Leanne E. Felkin
KSKen Suzuki
Ken Suzuki
Background— Therapeutic efficacy of bone marrow (BM) cell injection for treating ischemic chronic heart failure has not been established. In addition, experimental data are lacking on arrhythmia occurrence after BM cell injection. We hypothesized that therapeutic efficacy and arrhythmia occurrence induced by BM cell injection may be affected by the cell delivery route. Methods and Results— Three weeks after left coronary artery ligation, wild-type female rats were injected with 1×10 7 mononuclear BM cells derived from green fluorescent protein–transgenic male rats through either a direct intramyocardial or a retrograde intracoronary route. Both intramyocardial and intracoronary injection of BM cells demonstrated similar improvement in left ventricular ejection fraction measured by echocardiography and a similar graft size analyzed by real-time polymerase chain reaction for the Y chromosome–specific Sry gene. Noticeably, intramyocardial injection of BM cells induced frequent ventricular premature contractions (108±73 per hour at 7 days after BM cell injection), including multiform, consecutive ventricular premature contractions and ventricular tachycardia for the initial 14 days; intracoronary injection of BM cells and intramyocardial injection of phosphate-buffered saline rarely induced arrhythmias. Immunohistochemistry demonstrated that intramyocardial BM cell injection formed distinct cell clusters containing donor-derived cells and accumulated host-derived inflammatory cells in the infarct border zone, whereas intracoronary BM cell injection provided more homogeneous donor cell dissemination with less inflammation and without disrupting the native myocardial structure. Conclusions— BM cell injection is able to improve cardiac function in ischemic chronic heart failure but has a risk of arrhythmia occurrence when the intramyocardial route is used. Such arrhythmias may be prevented by using the intracoronary route.

18 September 2001 in Circulation
Verified
Journal Article
Closed access
PDF file
KSKen Suzuki
Ken Suzuki
BMBari Murtuza
Bari Murtuza
RSRyszard T. Smolenski
Ryszard T. Smolenski
ISIvan Andrew Sammut
Ivan Andrew Sammut
NSNoriko Suzuki
Noriko Suzuki
MYMagdi H. Yacoub
Magdi H. Yacoub
Background Vascular endothelial growth factor (VEGF) is a promising reagent for inducing myocardial angiogenesis. Skeletal myoblast transplantation has been shown to improve cardiac function in chronic heart failure models by regenerating muscle. We hypothesized that transplantation of VEGF-expressing myoblasts could effectively treat acute myocardial infarction by providing VEGF-induced cardioprotection through vasodilatation in the early phase, followed by angiogenesis effects in salvaging ischemic host myocardium combined with the functional benefits of newly formed, skeletal myoblast-derived muscle in the later phase. Methods and Results Primary rat skeletal myoblasts were transfected with the human VEGF165 gene using hemagglutinating virus of Japan-liposome with >95% transfection efficiency. Four million of these myoblasts (VEGF group), control-transfected myoblasts (control group), or medium only (medium group) was injected into syngeneic rat hearts 1 hour after left coronary artery occlusion. Myocardial VEGF-expression increased for 2 weeks in the VEGF group, resulting in enhanced angiogenesis without the formation of tumors. Grafted myoblasts had differentiated into multinucleated myotubes within host myocardium. Infarct size (33.3±1.4%, 38.1±1.4%, and 43.7±1.6% for VEGF, control, and medium groups, respectively; P=0.0005) was significantly reduced with VEGF treatment, and cardiac function improved in the VEGF group (maximum dP/dt: 4072.0±93.6, 3772.5±101.1, and 3482.5±90.6 mm Hg/s in the 3 groups, respectively; P=0.0011; minimum dP/dt: −504.2±68.5, −2311.3±57.0, and −2124.0±57.9 mm Hg/s, respectively; P=0.0008). Conclusions This combined strategy of cell transplantation with gene therapy could be of importance for the treatment of acute myocardial infarction.

20 May 2004 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
KSKen Suzuki
Ken Suzuki
BMBari Murtuza
Bari Murtuza
JBJonathan R. Beauchamp
Jonathan R. Beauchamp
RSRyszard T. Smolenski
Ryszard T. Smolenski
AVAnabel Varela‐Carver
Anabel Varela‐Carver
MYMagdi H. Yacoub
Magdi H. Yacoub
Survival and proliferation of skeletal myoblasts within the cardiac environment are crucial to the therapeutic efficacy of myoblast transplantation to the heart. We have analyzed the early dynamics of myoblasts implanted into the myocardium and investigated the mechanisms underlying graft attrition. At 10 min after implantation of [ 14 C]thymidine‐labeled male myoblasts into female mice hearts, 14 C measurement showed that 39.2 ± 3.0% of the grafted cells survived, and this steadily decreased to 16.0 ± 1.7% by 24 h and to 7.4 ± 0.9% by 72 h. PCR of male‐ specific Smcy gene calculated that the total (surviving plus proliferated) number of donor‐derived cells was 18.3 ± 1.6 and 23.3 ± 1.3% at 24 and 72 h, respectively, indicating that proliferation of the surviving cells began after 24 h. Acute inflammation became prominent by 24 h and was reduced by 72 h as indicated by myeloperoxidase activity and histological findings. Multiplex RT‐PCR revealed corresponding changes in IL‐1β, TGF‐β, IL‐6, and TNF‐α expression. Treatment with CuZn‐superoxide dismutase attenuated the initial rapid death and resulted in enhanced cell numbers afterward, giving a twofold increased total number at 72 h compared with the nontreatment. This effect was associated with reduced inflammatory response, suggesting a causative role for superoxide in the initial rapid graft death and subsequent inflammation. These data describe the early dynamics of myoblasts implanted into the myocardium and suggest that initial oxidative stress and following inflammatory response may be important mechanisms contributing to acute graft attrition, both of which could be potential therapeutic targets to improve the efficiency of cell transplantation to the heart.